keyword
MENU ▼
Read by QxMD icon Read
search

HAP VAP

keyword
https://www.readbyqxmd.com/read/27895901/prevention-of-hospital-acquired-pneumonia-in-non-ventilated-adult-patients-a-narrative-review
#1
REVIEW
Leonor Pássaro, Stephan Harbarth, Caroline Landelle
BACKGROUND: Pneumonia is one of the leading hospital-acquired infections worldwide and has an important impact. Although preventive measures for ventilator-associated pneumonia (VAP) are well known, less is known about appropriate measures for prevention of hospital-acquired pneumonia (HAP). AIM: The purpose of this narrative review is to provide an overview of the current standards for preventing HAP in non-ventilated adult patients. METHODS: A search of the literature up to May 2015 was conducted using Medline for guidelines published by national professional societies or professional medical associations...
2016: Antimicrobial Resistance and Infection Control
https://www.readbyqxmd.com/read/27763732/antibiotics-for-ventilator-associated-pneumonia
#2
REVIEW
Lauren E Arthur, Russell S Kizor, Adrian G Selim, Mieke L van Driel, Leonardo Seoane
BACKGROUND: Ventilator-associated pneumonia (VAP) is a significant cause of morbidity and mortality, complicating the medical course of approximately 10% of mechanically-ventilated patients, with an estimated attributable mortality of 13%. To treat VAP empirically, the American Thoracic Society currently recommends antibiotic therapy based on the patients' risk of colonisation by an organism with multidrug resistance. The selection of initial antibiotic therapy in VAP is important, as inappropriate initial antimicrobial treatment is associated with higher mortality and longer hospital stay in intensive care unit (ICU) patients...
October 20, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27521441/executive-summary-management-of-adults-with-hospital-acquired-and-ventilator-associated-pneumonia-2016-clinical-practice-guidelines-by-the-infectious-diseases-society-of-america-and-the-american-thoracic-society
#3
Andre C Kalil, Mark L Metersky, Michael Klompas, John Muscedere, Daniel A Sweeney, Lucy B Palmer, Lena M Napolitano, Naomi P O'Grady, John G Bartlett, Jordi Carratalà, Ali A El Solh, Santiago Ewig, Paul D Fey, Thomas M File, Marcos I Restrepo, Jason A Roberts, Grant W Waterer, Peggy Cruse, Shandra L Knight, Jan L Brozek
It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.These guidelines are intended for use by healthcare professionals who care for patients at risk for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), including specialists in infectious diseases, pulmonary diseases, critical care, and surgeons, anesthesiologists, hospitalists, and any clinicians and healthcare providers caring for hospitalized patients with nosocomial pneumonia...
September 1, 2016: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/27448108/injectable-and-biodegradable-composite-bone-filler-composed-of-poly-propylene-fumarate-and-calcium-phosphate-ceramic-for-vertebral-augmentation-procedure-an-in-vivo-porcine-study
#4
Chang-Chin Wu, Li-Ho Hsu, Shoichiro Sumi, Kai-Chiang Yang, Shu-Hua Yang
Despite its common usage in vertebral augmentation procedures (VAPs), shortcomings of commercial polymethylmethacrylate (PMMA) still remain. Accordingly, injectable and biodegradable composite cements, which are composed of poly(propylene fumarate)/α-tricalcium/hydroxyapatite (PPF/α-TCP/HAP) and PPF/tetracalcium phosphate/dicalcium phosphate (PPF/TtCP/DCP), were developed. A porcine model was used and cylindrical holes in critical size were created at the center of the lateral cortex of vertebral bodies of the lumbar spine...
July 22, 2016: Journal of Biomedical Materials Research. Part B, Applied Biomaterials
https://www.readbyqxmd.com/read/27418577/management-of-adults-with-hospital-acquired-and-ventilator-associated-pneumonia-2016-clinical-practice-guidelines-by-the-infectious-diseases-society-of-america-and-the-american-thoracic-society
#5
Andre C Kalil, Mark L Metersky, Michael Klompas, John Muscedere, Daniel A Sweeney, Lucy B Palmer, Lena M Napolitano, Naomi P O'Grady, John G Bartlett, Jordi Carratalà, Ali A El Solh, Santiago Ewig, Paul D Fey, Thomas M File, Marcos I Restrepo, Jason A Roberts, Grant W Waterer, Peggy Cruse, Shandra L Knight, Jan L Brozek
It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.These guidelines are intended for use by healthcare professionals who care for patients at risk for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), including specialists in infectious diseases, pulmonary diseases, critical care, and surgeons, anesthesiologists, hospitalists, and any clinicians and healthcare providers caring for hospitalized patients with nosocomial pneumonia...
September 1, 2016: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/27347712/emerging-drugs-for-nosocomial-pneumonia
#6
Adamantia Liapikou, Antoni Torres
INTRODUCTION: Hospital-acquired pneumonia (HAP) is one of the leading nosocomial infections worldwide and is associated with an elevated morbidity and mortality and increased hospital costs. Nevertheless, prompt and adequate antimicrobial treatment is mandatory following VAP development, especially in the face of multidrug resistant pathogens. AREAS COVERED: We searched Pubmed and ClinicalTrials.gov site reports in English language of phase III clinical trials, between 2000-2016 referring to the antibiotic treatment of nosocomial pneumonia...
September 2016: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/27344468/the-risk-factors-for-hospital-acquired-pneumonia-in-the-intensive-care-unit
#7
Marta Wałaszek, Alicja Kosiarska, Agnieszka Gniadek, Małgorzata Kołpa, Zdzisław Wolak, Wiesław Dobroś, Jolanta Siadek
INTRODUCTION: Patients in the intensive care units (ICU) are exposed to many factors that may cause hospital acquired pneumonia (HAP), a particular type of which is ventilator-associated pneumonia (VAP). The specific risk factors for developing VAP affect patients already on the day of their admission to a unit and are associated with their underlying diseases and invasive medical procedures, which they undergo. The aim of this study was to evaluate the risk factors for VAP associated with a patient and the used invasive treatment...
2016: Przegla̧d Epidemiologiczny
https://www.readbyqxmd.com/read/27329135/prevalence-of-pseudomonas-aeruginosa-and-antimicrobial-resistant-pseudomonas-aeruginosa-in-patients-with-pneumonia-in-mainland-china-a-systematic-review-and-meta-analysis
#8
REVIEW
Chengyi Ding, Zhirong Yang, Jing Wang, Xinran Liu, Yu Cao, Yuting Pan, Lizhong Han, Siyan Zhan
OBJECTIVE: To estimate the prevalence of Pseudomonas aeruginosa and antimicrobial-resistant P. aeruginosa in ventilator-associated pneumonia (VAP), hospital-acquired pneumonia (HAP), and community-acquired pneumonia (CAP) in mainland China. METHODS: Meta-analyses of 50 studies published from 2010 to 2014 were conducted, followed by pre-defined subgroup analyses and meta-regressions. RESULTS: P. aeruginosa accounted for 19.4% (95% confidence interval (CI) 17...
August 2016: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/27249225/presence-of-the-panton-valentine-leukocidin-genes-in-methicillin-resistant-staphylococcus-aureus-is-associated-with-severity-and-clinical-outcome-of-hospital-acquired-pneumonia-in-a-single-center-study-in-china
#9
Chuanling Zhang, Liang Guo, Xu Chu, Limeng Shen, Yuanyu Guo, Huali Dong, Jianfeng Mao, Stijn van der Veen
The Panton-Valentine leukocidin (PVL) genes of methicillin-resistant Staphylococcus aureus (MRSA) have previously been associated with severe infections. Here, the impact of the PVL genes on severity of disease and clinical outcome of patients with hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) due to MRSA was investigated in a single center observational study in a hospital in China. HAP due to MRSA was diagnosed in 100 patients and 13 of the patients were PVL positive, while VAP was diagnosed in 5 patients and 2 were PVL positive...
2016: PloS One
https://www.readbyqxmd.com/read/27003315/epidemiology-of-hospital-acquired-pneumonia-results-of-a-central-european-multicenter-prospective-observational-study-compared-with-data-from-the-european-region
#10
Tomas Herkel, Radovan Uvizl, Lenka Doubravska, Milan Adamus, Tomas Gabrhelik, Miroslava Htoutou Sedlakova, Milan Kolar, Vojtech Hanulik, Vendula Pudova, Katerina Langova, Roman Zazula, Tomas Rezac, Michal Moravec, Pavel Cermak, Pavel Sevcik, Jan Stasek, Jan Malaska, Alena Sevcikova, Marketa Hanslianova, Zdenek Turek, Vladimir Cerny, Pavla Paterova
BACKGROUND: Hospital-acquired pneumonia (HAP) is associated with high mortality. In Central Europe, there is a dearth of information on the prevalence and treatment of HAP. This project was aimed at collecting multicenter epidemiological data on patients with HAP in the Czech Republic and comparing them with supraregional data. METHODS: This prospective, multicenter, observational study processed data from a database supported by a Czech Ministry of Health grant project...
September 2016: Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
https://www.readbyqxmd.com/read/26998623/investigational-drugs-in-phase-i-and-phase-ii-clincial-trials-for-the-treatment-of-hospital-acquired-pneumonia
#11
Vicenç Falcó, Joaquin Burgos, Elisabeth Papiol, Ricard Ferrer, Benito Almirante
INTRODUCTION: Hospital acquired pneumonia (HAP) is one of the main infections acquired by patients during a stay in hospital. The main issue when dealing with patients with HAP and ventilator associated pneumonia (VAP) is the increasing role of multi-drug resistant organisms (MDROs). AREAS COVERED: In this review the authors summarize the actual situation of MDROs as a cause of HAP and VAP. They also review the current treatment options stated in the most important international guidelines...
June 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/26301604/short-course-versus-prolonged-course-antibiotic-therapy-for-hospital-acquired-pneumonia-in-critically-ill-adults
#12
REVIEW
Richard Pugh, Chris Grant, Richard P D Cooke, Ged Dempsey
BACKGROUND: Pneumonia is the most common hospital-acquired infection affecting patients in the intensive care unit (ICU). However, current national guidelines for the treatment of hospital-acquired pneumonia (HAP) are several years old and the diagnosis of pneumonia in mechanically ventilated patients (VAP) has been subject to considerable recent attention. The optimal duration of antibiotic therapy for HAP in the critically ill is uncertain. OBJECTIVES: To assess the effectiveness of short versus prolonged-course antibiotics for HAP in critically ill adults, including patients with VAP...
2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26190444/pseudomonas-aeruginosa-nosocomial-pneumonia-impact-of-pneumonia-classification
#13
COMPARATIVE STUDY
Scott T Micek, Marin H Kollef, Antoni Torres, Catherine Chen, Jordi Rello, Jean Chastre, Massimo Antonelli, Tobias Welte, Bernard Clair, Helmut Ostermann, Esther Calbo, Richard Wunderink, Francesco Menichetti, Garrett Schramm, Vandana Menon
OBJECTIVE: To describe and compare the mortality associated with nosocomial pneumonia due to Pseudomonas aeruginosa (Pa-NP) according to pneumonia classification (community-onset pneumonia [COP], hospital-acquired pneumonia [(HAP], and ventilator-associated pneumonia [VAP]). DESIGN: We conducted a retrospective cohort study of adults with Pa-NP. We compared mortality for Pa-NP among patients with COP, HAP, and VAP and used logistic regression to identify risk factors for hospital mortality and inappropriate initial antibiotic therapy (IIAT)...
October 2015: Infection Control and Hospital Epidemiology
https://www.readbyqxmd.com/read/25956849/ceftaroline-fosamil-for-the-treatment-of-hospital-acquired-pneumonia-and-ventilator-associated-pneumonia
#14
MULTICENTER STUDY
Keith S Kaye, George Udeani, Phillip Cole, Hillel David Friedland
OBJECTIVES: Ceftaroline fosamil is a novel cephalosporin with bactericidal activity against common pathogens associated with hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Ceftaroline is inactive against extended-spectrum β-lactamase-producing or AmpC-overexpressing Enterobacteriaceae and has limited activity against Pseudomonas aeruginosa. CAPTURE is a multicenter, retrospective study designed to collect information on contemporary clinical use of ceftaroline fosamil in the USA...
2015: Hospital Practice (Minneapolis)
https://www.readbyqxmd.com/read/25742187/understanding-the-concept-of-health-care-associated-pneumonia-in-lung-transplant-recipients
#15
Federico Palacio, Luis F Reyes, Deborah J Levine, Juan F Sanchez, Luis F Angel, Juan F Fernandez, Stephanie M Levine, Jordi Rello, Ali Abedi, Marcos I Restrepo
BACKGROUND: Limited data are available regarding the etiologic impact of health care-associated pneumonia (HCAP) in lung transplant recipients. Therefore, our aim was to evaluate the microbiologic differences between HCAP and hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) in lung transplant recipients with a radiographically confirmed diagnosis of pneumonia. METHODS: We performed a retrospective cohort study of lung transplant recipients with pneumonia at one transplant center over a 7-year period...
August 2015: Chest
https://www.readbyqxmd.com/read/25688601/participation-of-elderly-adults-in-randomized-controlled-trials-addressing-antibiotic-treatment-of-pneumonia
#16
REVIEW
Tomer Avni, Shahaf Shiver-Ofer, Leonard Leibovici, Evelina Tacconelli, Giulia DeAngelis, Barry Cookson, Leonardo Pagani, Mical Paul
OBJECTIVES: To examine how relevant current evidence on antibiotic treatment of pneumonia is for elderly adults. DESIGN: Systematic review. SETTING: Randomized controlled trials (RCTs; N = 43) comparing different antibiotics and prospective observational studies (N = 182) published since 2005. PARTICIPANTS: Adults with community-acquired (CAP), healthcare-associated (HCAP), hospital-acquired (HAP), or ventilator-associated (VAP) pneumonia...
February 2015: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/25601458/time-to-guideline-based-empiric-antibiotic-therapy-in-the-treatment-of-pneumonia-in-a-community-hospital-a-retrospective-review
#17
Beth L Erwin, Jeffrey A Kyle, Leland N Allen
PURPOSE: The 2005 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines for hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and health care-associated pneumonia (HCAP) stress the importance of initiating prompt appropriate empiric antibiotic therapy. This study's purpose was to determine the percentage of patients with HAP, VAP, and HCAP who received guideline-based empiric antibiotic therapy and to determine the average time to receipt of an appropriate empiric regimen...
August 2016: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/25440125/pneumonia-challenges-in-the-definition-diagnosis-and-management-of-disease
#18
REVIEW
Julie Ottosen, Heather Evans
Defining health care-associated pneumonia, which includes both hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), is problematic and controversial. Aspiration pneumonia is often included as a subtype of HAP but may be related to community-acquired aspiration events. Scoring systems exist and new surveillance guidelines have been implemented to make early recognition of pneumonia more precise and objective. Management and prevention should follow recommendations, including early empirical therapy, targeted therapy, and limited duration of treatment...
December 2014: Surgical Clinics of North America
https://www.readbyqxmd.com/read/25423417/-antibiotic-treatment-of-pneumonia-what-s-at-cap-hap-and-vap-to-consider
#19
T Welte
No abstract text is available yet for this article.
November 2014: Drug Research
https://www.readbyqxmd.com/read/25117196/ceftobiprole-medocaril-a-review-of-its-use-in-patients-with-hospital-or-community-acquired-pneumonia
#20
REVIEW
Yahiya Y Syed
Ceftobiprole, the active metabolite of the prodrug ceftobiprole medocaril (Zevtera(®)), is a new generation broad-spectrum intravenous cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Ceftobiprole exhibits potent in vitro activity against a number of Gram-positive and Gram-negative pathogens associated with hospital-acquired pneumonia (HAP) and community-acquired pneumonia (CAP). It is the first cephalosporin monotherapy approved in the EU for the treatment of both HAP (excluding ventilator associated-pneumonia [VAP]) and CAP...
September 2014: Drugs
keyword
keyword
75929
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"